# Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)

> **NCT04937907** · PHASE2 · COMPLETED · sponsor: **Shanghai Children's Hospital** · enrollment: 50 (actual)

## Conditions studied

- Alport Syndrome, X-Linked

## Interventions

- **DRUG:** Hydroxychloroquine Sulfate 100 milligram (mg) Tab
- **DRUG:** Benazepril hydrochloride 10 milligram (mg) Tab

## Key facts

- **NCT ID:** NCT04937907
- **Lead sponsor:** Shanghai Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-08
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937907, "Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04937907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*